Showing results (41-50 of 62) with videos related to
Sort By:
Pageof 7
Lung Cancer (Amsterdam, Netherlands)|March 12, 2004
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing diseaseRalph G Zinner, Bonnie S Glisson, Frank V Fossella, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 17, 2023
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With ChemotherapyNasser Hanna, Frances A Shepherd, Frank V Fossella, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 17, 2020
Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLCOlsi Gjyshi, Ting Xu, Adnan Elhammali, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2018
Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung CancerZhongxing Liao, J Jack Lee, Ritsuko Komaki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2004
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapyNasser Hanna, Frances A Shepherd, Frank V Fossella, et al.Cancer Treatment and Research Communications|January 20, 2022
Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung CancerSteven H Lin, Heather Y Lin, Vivek Verma, et al.Cancer|July 19, 2002
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapyRoy S Herbst, Fadlo R Khuri, Charles Lu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumorsFadlo R Khuri, Bonnie S Glisson, Edward S Kim, et al.International Journal of Radiation Oncology, Biology, Physics|March 31, 2004
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trialRitsuko Komaki, Jin Soo Lee, Luka Milas, et al.JTO Clinical and Research Reports|August 31, 2023
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLCKaiwen Wang, Robyn Du, Sinchita Roy-Chowdhuri, et al.Pageof 7